This site is intended for health professionals only

At the heart of general practice since 1960

pulse june2020 80x101px
Read the latest issue online

GPs go forth

Paper of the Day- High dose methotrexate cuts RA disability

Intensifying methotrexate early in rheumatoid arthritis increases the chance of remission, say Dutch researchers.

The two year study randomised 299 patients into two groups. The first, conventional treatment group were seen every three months and had their drug doses adjusted according to the clinician's judgement. The second group were given a more intensive treatment approach. They were seen every month to have their MTX dose adjusted using a computerised decision making tool. Symptoms scores were fed into the program which then decided if treatment response was great enough. If not, the dose of methotrexate was increased.
This meant the maximum dose of MTX was reached in just 18 weeks in the intensive treatment versus 52 weeks for those received conventional treatment. Fifty per cent of patients treated intensively had least one remission in two years follow-up compared to 37% in the conventional group (p=0.03).

Ann Rheum Dis 2007;66:1443-1449.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say